ArticleFrontiers in medicine2026
Successful upadacitinib treatment in anti-TNF-refractory intestinal Behçet's disease: a case report and literature review.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Behçet's disease (BD) is a persistent inflammatory vasculitis affecting various vessel types across multiple organ systems. It clinically presents recurrent oral and genital ulcers, ocular inflammation, and various skin manifestations. Etiology remains multifactorial, involving genetic susceptibility, immune system dysregulation, and environmental triggers such as infections. Intestinal involvement represents a rare but particularly severe form of BD, whose clinical features frequently resemble those of inflammatory bowel diseases (IBD), complicating differential diagnosis and management. Case presentation: We report a case of a 23-year-old male with progressive postprandial abdominal pain, diarrhea, and marked weight loss. His clinical history was notable for recurrent oral aphthae, genital ulcers, and perianal infections. Colonoscopic examination revealed circumferential ulceration, mucosal edema, contact bleeding, and significant narrowing of the ileocecal lumen. Histopathological analysis indicated chronic active inflammation in the absence of granulomas or definitive vasculitis. Infectious and neoplastic causes were systematically excluded. The patient was diagnosed with intestinal BD. Although initial therapy with infliximab yielded partial clinical improvement, drug-level monitoring revealed suboptimal trough levels, indicating secondary loss of response. Subsequently, treatment was transitioned to the Janus kinase (JAK) inhibitor upadacitinib, which led to full symptom resolution and mucosal healing on follow-up endoscopy. Conclusion: This case underscores the diagnostic and therapeutic challenges associated with intestinal BD, especially in distinguishing it from Crohn's disease and addressing resistance to anti-TNF agents. Our findings suggest that JAK inhibitors like upadacitinib may offer a promising alternative for patients with refractory intestinal BD. Incorporating therapeutic drug monitoring into clinical practice allows for personalized, adaptive treatment adjustments, potentially improving long-term outcomes in complex cases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.